Announced
Completed
Financials
Tags
biotech
Acquisition
Majority
Completed
Friendly
Denmark
Biotechnology
Domestic
Private
Single Bidder
Synopsis
Novo Nordisk, a global healthcare company, completed the acquisition of Embark Biotech, a Danish biotech company, for €471m. "Novo Nordisk has been engaged in obesity research for 25 years, and we continuously search for new ways to address this serious chronic disease. We are excited about the opportunity to advance Embark Biotech's lead program and look forward to co-creating novel treatments for cardiometabolic diseases with Embark Laboratories to complement our in-house R&D," Brian Finan, Novo Nordisk Vice President of Obesity Research.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.